Some lymphomas, including peripheral T-cell lymphomas (PTCL), have too much of an enzyme called aurora kinase, which makes lymphoma cells grow and divide at a high rate. MLN8237 is an investigational drug that blocks aurora kinase. In early studies, several people with PTCL who took MLN8237 experienced shrinkage or disappearance of their cancers.
The purpose of this study is to assess the safety and effectiveness of MLN8237 in patients with PTCL that has returned or persisted despite prior therapy. MLN8237 is a pill that is taken orally (by mouth).